MERUS NV (MRUS)
NL0011606264 - Common Stock
MERUS NV
NASDAQ:MRUS (1/3/2025, 8:00:01 PM)
After market: 43.16 0 (0%)43.16
+0.86 (+2.03%)
Company Profile
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 172 full-time employees. The company went IPO on 2016-05-19. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The firm operates in the Netherlands and United States.
Company Info
MERUS NV
Uppsalalaan 17, 3rd & 4th floor
Utrecht UTRECHT 3584
P: 31850162500
CEO: Sven A. Lundberg
Employees: 201
Website: https://merus.nl/
MRUS News
19 days ago - Merus N.V.Merus annonce le traitement du premier patient dans le cadre d’un essai de phase 2 portant sur le pétosemtamab dans le CCRm en 3e ligne et lignes ultérieuresUTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 17 déc. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une société spécialisée dans l’oncologie...
19 days ago - Merus N.V.Merus gibt Verabreichung von petosemtamab an ersten Patienten in Phase-II-Studie bei 3L+ mCRC bekanntUTRECHT, Niederlande und CAMBRIDGE, Massachusetts, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), ein Onkologie-Unternehmen im klinischen...
19 days ago - Merus N.V.Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC19 days ago - Merus N.V.Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRCUTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing...
a month ago - Merus N.V.Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/mÉtude du pétosemtamab en association avec le pembrolizumab en 1re ligne de traitement dans le CETC r/m exprimant PD-L1 en cours, avec une actualisation des...
a month ago - Merus N.V.Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCCStudie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L r/m PD-L1-exprimierendem HNSCC läuft, Aktualisierung der klinischen Daten für 2025 geplant ...
MRUS Twits
Here you can normally see the latest stock twits on MRUS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
